Irma Egoavil, Director General of Ferring Pharmaceuticals Mexico, spoke with Mexico Health Review on the company’s strategy for the country. 


Q: Ferring operates in many areas, some quite specialized. Which are the most relevant for the Mexican market?

A: Our urology portfolio contains a product aimed at hormonal dependent prostatic cancer, an antagonist that enables fast and safe disease control without increasing cardiovascular risk, a relevant factor for the Mexican population. In addition, in August 2017 we will be launching a product for the treatment of patients with erectile dysfunction. Although it would be a first-line treatment, it will be particularly useful for patients with metabolic syndrome, obesity or cardiovascular disease because this segment is at risk if systemic treatment options are used.

Q: What is Ferring’s most interesting project at this time?

A: Ferring is not a Big Pharma nor an orphan drugs manufacturer but a specialized company attending niche pathologies. We are becoming a more technology-oriented company, which is due to the areas in which we work. For example, we manage a portfolio for patients with chronic intestinal disease, which is not so frequent, is difficult to diagnose and patients need a lot of follow-up during the treatment. We have been providing digital tools to provide such follow-ups for the past three years.

Q: How can technological innovations help patients?

A: The way they work varies according to therapeutic areas. For example, we have an app for patients with inflammatory bowel disease that provides information on the different stages of the disease and the reasons behind its progression. The main issue for these patients is that even though the disease may be controlled, there could be a specific event that pushes it to another stage. We provide support and teach them to identify symptoms. Another program helps patients with prostatic cancer track the disease properly, providing them with access to prostatic antigen testing.

By jakobking85. CC0 Creative Commons.

Ferring also runs a program called BB en casa (Baby at home) that helps patients with a fertility need who do not have the purchasing power to access treatment. The major problem in reproductive health is that all costs are paid for fully out-of-pocket, so not all patients are able to undergo treatment. As world leaders in reproductive care, through our Proteger (Protect) program we work with INCan and other associations to identify and support female patients who have cancer and could potentially have a future reproductive need. Our program enables them to protect their ovules and thus ensure future possibilities of getting pregnant. We work mostly with breast cancer patients because it is a disease that can be cured if detected early enough.

Q: What internal and external factors have contributed to the company’s growth?

A: Ferring has enjoyed success in the private and the public sectors due to our portfolio and because we are committed to helping people become parents and to keeping mothers and babies healthy, from conception to birth. Over one-third of our investment in R&D targets innovative treatments in reproductive and maternal health but we are also passionate about making a difference to people’s health and quality of life through our work. Something we are working on is diversification. We supply to 18 countries in the region, which has also helped us to grow and we have striven to differentiate ourselves and bring products here that could have an impact on the population.

Q: Which products will you bring to Mexico?

A: We will be launching three new products in the short to medium term. The first is the treatment for erectile dysfunction. The others are focused on fertility. One is a biotech product that is a recombinant treatment, different from what is on the market because it enables doctors to tailor doses to a patient’s specific needs. The other is a treatment that makes it easier for a fertilized egg to attach to the uterus at the beginning of pregnancy. This treatment has an innovative application and dissolution method that supports the proper absorption of the drug, which differentiates it from other intravaginal alternatives. This will be on the market in September 2017.

If you want to get more information or participate with relevant insights regarding the Mexican healthcare industry visit Mexico Health Review.

Tagged with →  
Share →

Leave a Reply

Your email address will not be published. Required fields are marked *